FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387519982> ?p ?o ?g. }

• W4387519982 abstract "Abstract Background The use of decentralised clinical trials (which bring trials to patients through remote processes and technology versus central on-site visits) has been thought to be a potential solution to common recruitment and retention barriers. However, there is a lack of evidence to understand the experiences, needs and preferences of the public to inform trial methodologies that appeal to different populations. We report participant experiences of SAFA, a partially decentralised randomised clinical trial, to inform the methodology used in future dermatology trials that aim to appeal to women aged 18 and over. Methods Participants of the SAFA (Spironolactone for Adult Female Acne) trial were invited to take part in a qualitative semi-structured interview to explore their experience and perspectives of taking part in the trial. Questions focused on their experience of using decentralised methods to access and enrol in the trial (e.g. social media advertising), in addition to the decentralised trial visit and data collection methods used throughout. Interviews were conducted remotely, recorded, and transcribed. Data were analysed using reflexive thematic analysis. Results Twelve SAFA participants (all women, age range 22–36 years) were interviewed. Initially, participants were influenced to enrol by trusted online information, the feeling of validation the trial provided, and the convenience and flexibility offered by the decentralised methods and research staff made participants feel valued and enabled them to engage in the trial with minimal interference to existing commitments. SAFA participants were generally accepting of trial demands, such as the text-heavy paperwork and on-site visits for blood collection and highlighted several areas relevant for trial conduct going forwards including where decentralised methods may (and may not) be accepted and how trial accessibility and understanding could be improved. Conclusions The study has shown that decentralised methods used by responsive and approachable staff were widely accepted in the SAFA trial. Interviewees found the methods adopted in the SAFA trial helped the trial to fit with their needs and promoted a sense of feeling valued that encouraged ongoing trial engagement. Decentralised methods should be considered favourably when designing a dermatology trial as they can potentially enhance both recruitment and retention. Trial registration number ISRCTN 12892056. Registered on October 15, 2018." @default.
• W4387519982 created "2023-10-12" @default.
• W4387519982 creator A5004765815 @default.
• W4387519982 creator A5028646703 @default.
• W4387519982 creator A5033236441 @default.
• W4387519982 creator A5042649331 @default.
• W4387519982 creator A5049466524 @default.
• W4387519982 creator A5051116590 @default.
• W4387519982 creator A5059207498 @default.
• W4387519982 creator A5063266899 @default.
• W4387519982 creator A5081937782 @default.
• W4387519982 creator A5092348986 @default.
• W4387519982 creator A5092348987 @default.
• W4387519982 date "2023-10-12" @default.
• W4387519982 modified "2023-10-14" @default.
• W4387519982 title "Factors that influence women’s enrolment and ongoing participation in a partially decentralised randomised controlled dermatology trial: a qualitative interview study with participants in the SAFA (Spironolactone for Adult Female Acne) trial" @default.
• W4387519982 cites W1785898356 @default.
• W4387519982 cites W2029187567 @default.
• W4387519982 cites W2144829163 @default.
• W4387519982 cites W2149868499 @default.
• W4387519982 cites W2172480383 @default.
• W4387519982 cites W2305278139 @default.
• W4387519982 cites W2587949891 @default.
• W4387519982 cites W2788630491 @default.
• W4387519982 cites W2789745741 @default.
• W4387519982 cites W2950504429 @default.
• W4387519982 cites W2980920892 @default.
• W4387519982 cites W3010102662 @default.
• W4387519982 cites W3011041837 @default.
• W4387519982 cites W3028146832 @default.
• W4387519982 cites W3041737230 @default.
• W4387519982 cites W3093637141 @default.
• W4387519982 cites W3137162530 @default.
• W4387519982 cites W3153321771 @default.
• W4387519982 cites W3186748106 @default.
• W4387519982 cites W3195755593 @default.
• W4387519982 cites W3207785334 @default.
• W4387519982 cites W4200412997 @default.
• W4387519982 cites W4210344100 @default.
• W4387519982 cites W4281691378 @default.
• W4387519982 cites W4319304541 @default.
• W4387519982 cites W4376636540 @default.
• W4387519982 doi "https://doi.org/10.1186/s13063-023-07630-4" @default.
• W4387519982 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37821899" @default.
• W4387519982 hasPublicationYear "2023" @default.
• W4387519982 type Work @default.
• W4387519982 citedByCount "0" @default.
• W4387519982 crossrefType "journal-article" @default.
• W4387519982 hasAuthorship W4387519982A5004765815 @default.
• W4387519982 hasAuthorship W4387519982A5028646703 @default.
• W4387519982 hasAuthorship W4387519982A5033236441 @default.
• W4387519982 hasAuthorship W4387519982A5042649331 @default.
• W4387519982 hasAuthorship W4387519982A5049466524 @default.
• W4387519982 hasAuthorship W4387519982A5051116590 @default.
• W4387519982 hasAuthorship W4387519982A5059207498 @default.
• W4387519982 hasAuthorship W4387519982A5063266899 @default.
• W4387519982 hasAuthorship W4387519982A5081937782 @default.
• W4387519982 hasAuthorship W4387519982A5092348986 @default.
• W4387519982 hasAuthorship W4387519982A5092348987 @default.
• W4387519982 hasBestOaLocation W43875199821 @default.
• W4387519982 hasConcept C122980154 @default.
• W4387519982 hasConcept C126322002 @default.
• W4387519982 hasConcept C141071460 @default.
• W4387519982 hasConcept C144024400 @default.
• W4387519982 hasConcept C15744967 @default.
• W4387519982 hasConcept C159110408 @default.
• W4387519982 hasConcept C168563851 @default.
• W4387519982 hasConcept C17744445 @default.
• W4387519982 hasConcept C190248442 @default.
• W4387519982 hasConcept C199539241 @default.
• W4387519982 hasConcept C36289849 @default.
• W4387519982 hasConcept C512399662 @default.
• W4387519982 hasConcept C518677369 @default.
• W4387519982 hasConcept C535046627 @default.
• W4387519982 hasConcept C71924100 @default.
• W4387519982 hasConcept C74196892 @default.
• W4387519982 hasConcept C77805123 @default.
• W4387519982 hasConceptScore W4387519982C122980154 @default.
• W4387519982 hasConceptScore W4387519982C126322002 @default.
• W4387519982 hasConceptScore W4387519982C141071460 @default.
• W4387519982 hasConceptScore W4387519982C144024400 @default.
• W4387519982 hasConceptScore W4387519982C15744967 @default.
• W4387519982 hasConceptScore W4387519982C159110408 @default.
• W4387519982 hasConceptScore W4387519982C168563851 @default.
• W4387519982 hasConceptScore W4387519982C17744445 @default.
• W4387519982 hasConceptScore W4387519982C190248442 @default.
• W4387519982 hasConceptScore W4387519982C199539241 @default.
• W4387519982 hasConceptScore W4387519982C36289849 @default.
• W4387519982 hasConceptScore W4387519982C512399662 @default.
• W4387519982 hasConceptScore W4387519982C518677369 @default.
• W4387519982 hasConceptScore W4387519982C535046627 @default.
• W4387519982 hasConceptScore W4387519982C71924100 @default.
• W4387519982 hasConceptScore W4387519982C74196892 @default.
• W4387519982 hasConceptScore W4387519982C77805123 @default.
• W4387519982 hasFunder F4320334661 @default.
• W4387519982 hasIssue "1" @default.
• W4387519982 hasLocation W43875199821 @default.
• W4387519982 hasLocation W43875199822 @default.
• W4387519982 hasOpenAccess W4387519982 @default.
• W4387519982 hasPrimaryLocation W43875199821 @default.

• next